Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.44
NYSE:GSK's Cash to Debt is ranked lower than
75% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. NYSE:GSK: 0.44 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:GSK' s 10-Year Cash to Debt Range
Min: 0.06  Med: 0.53 Max: N/A
Current: 0.44
Equity to Asset 0.13
NYSE:GSK's Equity to Asset is ranked lower than
95% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:GSK: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:GSK' s 10-Year Equity to Asset Range
Min: 0.11  Med: 0.25 Max: 0.4
Current: 0.13
0.11
0.4
Interest Coverage 5.23
NYSE:GSK's Interest Coverage is ranked lower than
87% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2854.00 vs. NYSE:GSK: 5.23 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:GSK' s 10-Year Interest Coverage Range
Min: 0.81  Med: 11.99 Max: 28.06
Current: 5.23
0.81
28.06
F-Score: 7
Z-Score: 1.99
M-Score: -1.91
WACC vs ROIC
8.86%
52.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 46.89
NYSE:GSK's Operating margin (%) is ranked higher than
98% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.78 vs. NYSE:GSK: 46.89 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:GSK' s 10-Year Operating margin (%) Range
Min: 1.68  Med: 29.06 Max: 36.94
Current: 46.89
1.68
36.94
Net-margin (%) 41.44
NYSE:GSK's Net-margin (%) is ranked higher than
96% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. NYSE:GSK: 41.44 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:GSK' s 10-Year Net-margin (%) Range
Min: 5.76  Med: 20.71 Max: 23.94
Current: 41.44
5.76
23.94
ROE (%) 162.95
NYSE:GSK's ROE (%) is ranked higher than
100% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. NYSE:GSK: 162.95 )
Ranked among companies with meaningful ROE (%) only.
NYSE:GSK' s 10-Year ROE (%) Range
Min: 17.3  Med: 62.19 Max: 153.51
Current: 162.95
17.3
153.51
ROA (%) 20.85
NYSE:GSK's ROA (%) is ranked higher than
91% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.32 vs. NYSE:GSK: 20.85 )
Ranked among companies with meaningful ROA (%) only.
NYSE:GSK' s 10-Year ROA (%) Range
Min: 3.84  Med: 17.77 Max: 26.32
Current: 20.85
3.84
26.32
ROC (Joel Greenblatt) (%) 124.97
NYSE:GSK's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.13 vs. NYSE:GSK: 124.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 40.79  Med: 83.56 Max: 148.93
Current: 124.97
40.79
148.93
Revenue Growth (3Y)(%) -4.10
NYSE:GSK's Revenue Growth (3Y)(%) is ranked lower than
78% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NYSE:GSK: -4.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:GSK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.1  Med: 5.40 Max: 91
Current: -4.1
-4.1
91
EBITDA Growth (3Y)(%) -18.40
NYSE:GSK's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 492 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. NYSE:GSK: -18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:GSK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.4  Med: 7.70 Max: 85.9
Current: -18.4
-18.4
85.9
EPS Growth (3Y)(%) -17.90
NYSE:GSK's EPS Growth (3Y)(%) is ranked lower than
76% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NYSE:GSK: -17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:GSK' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.2  Med: 5.40 Max: 93.9
Current: -17.9
-30.2
93.9
» NYSE:GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

GSK Guru Trades in Q3 2014

David Dreman 1,328 sh (New)
Kahn Brothers 51,000 sh (New)
HOTCHKIS & WILEY 10,804,564 sh (+118.31%)
NWQ Managers 208,125 sh (+39.82%)
Charles Brandes 3,415,717 sh (+36.63%)
Jeff Auxier 133,518 sh (+22.92%)
John Rogers 1,005,634 sh (+1.71%)
Ken Fisher 11,488,594 sh (+1.08%)
Manning & Napier Advisors, Inc 333,460 sh (+0.58%)
Murray Stahl 24,022 sh (+0.13%)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Louis Moore Bacon 300,000 sh (unchged)
James Barrow 270,900 sh (unchged)
Pioneer Investments 331,758 sh (unchged)
John Hussman 323,500 sh (unchged)
Bill Frels Sold Out
Joel Greenblatt 83,462 sh (-0.08%)
Tweedy Browne 140,278 sh (-1.29%)
PRIMECAP Management 4,874,635 sh (-5.47%)
Jim Simons 6,827,600 sh (-23.02%)
Dodge & Cox 38,589,161 sh (-35.93%)
Diamond Hill Capital 14,902 sh (-92.14%)
» More
Q4 2014

GSK Guru Trades in Q4 2014

Pioneer Investments 1,206,201 sh (+263.58%)
Diamond Hill Capital 54,042 sh (+262.65%)
HOTCHKIS & WILEY 12,213,885 sh (+13.04%)
Manning & Napier Advisors, Inc 356,579 sh (+6.93%)
John Rogers 1,044,923 sh (+3.91%)
Jeff Auxier 138,693 sh (+3.88%)
James Barrow 270,900 sh (unchged)
First Eagle Investment 1 sh (unchged)
Louis Moore Bacon 500,000 sh (unchged)
Francis Chou 18,000 sh (unchged)
Kahn Brothers 51,000 sh (unchged)
David Dreman Sold Out
PRIMECAP Management 4,873,235 sh (-0.03%)
Joel Greenblatt 83,233 sh (-0.27%)
Murray Stahl 23,723 sh (-1.24%)
NWQ Managers 204,625 sh (-1.68%)
Charles Brandes 3,281,780 sh (-3.92%)
Tweedy Browne 134,293 sh (-4.27%)
Ken Fisher 10,765,004 sh (-6.30%)
John Hussman 300,000 sh (-7.26%)
Jim Simons 6,006,800 sh (-12.02%)
Dodge & Cox 23,959,301 sh (-37.91%)
» More
Q1 2015

GSK Guru Trades in Q1 2015

Sarah Ketterer 439,614 sh (New)
NWQ Managers 456,380 sh (+123.03%)
Diamond Hill Capital 93,778 sh (+73.53%)
Charles Brandes 3,879,073 sh (+18.20%)
Kahn Brothers 58,200 sh (+14.12%)
HOTCHKIS & WILEY 12,302,975 sh (+0.73%)
Joel Greenblatt 83,578 sh (+0.41%)
Pioneer Investments 1,208,920 sh (+0.23%)
Murray Stahl 23,773 sh (+0.21%)
Francis Chou 18,000 sh (unchged)
James Barrow 270,900 sh (unchged)
John Rogers 1,044,933 sh (unchged)
First Eagle Investment 1 sh (unchged)
John Hussman Sold Out
Ken Fisher 10,757,080 sh (-0.07%)
Manning & Napier Advisors, Inc 349,605 sh (-1.96%)
Dodge & Cox 23,436,551 sh (-2.18%)
Tweedy Browne 131,346 sh (-2.19%)
PRIMECAP Management 4,597,935 sh (-5.65%)
Jeff Auxier 71,417 sh (-48.51%)
Jim Simons 2,612,600 sh (-56.51%)
» More
Q2 2015

GSK Guru Trades in Q2 2015

Jeff Auxier 146,482 sh (+105.11%)
Diamond Hill Capital 169,372 sh (+80.61%)
Jim Simons 3,246,100 sh (+24.25%)
John Rogers 1,214,427 sh (+16.22%)
Sarah Ketterer 507,631 sh (+15.47%)
NWQ Managers 510,500 sh (+11.86%)
Charles Brandes 4,313,622 sh (+11.20%)
Pioneer Investments 1,326,663 sh (+9.74%)
Ken Fisher 11,533,371 sh (+7.22%)
Murray Stahl 23,823 sh (+0.21%)
Louis Moore Bacon 100,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Kahn Brothers 58,200 sh (unchged)
Francis Chou 18,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
PRIMECAP Management 4,595,385 sh (-0.06%)
Tweedy Browne 128,285 sh (-2.33%)
Joel Greenblatt 80,157 sh (-4.09%)
HOTCHKIS & WILEY 11,615,471 sh (-5.59%)
James Barrow 252,300 sh (-6.87%)
Dodge & Cox 12,476,998 sh (-46.76%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Oct 17, 2014

We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Jun 26, 2014

Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014
During the third quarter, Irving Kahn (Trades, Portfolio) of Kahn Brothers added only one position to the portfolio, and increased his holdings in just two companies. The majority of his activity was reducing his positions in 13 companies. Read more...
Diamond Hill Capital Comments on GlaxoSmithKline PLC
We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 6.70
GSK's P/E(ttm) is ranked higher than
95% of the 479 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.40 vs. GSK: 6.70 )
Ranked among companies with meaningful P/E(ttm) only.
GSK' s 10-Year P/E(ttm) Range
Min: 6.65  Med: 15.12 Max: 40.41
Current: 6.7
6.65
40.41
Forward P/E 17.64
GSK's Forward P/E is ranked higher than
66% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. GSK: 17.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 6.80
GSK's PE(NRI) is ranked higher than
95% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.40 vs. GSK: 6.80 )
Ranked among companies with meaningful PE(NRI) only.
GSK' s 10-Year PE(NRI) Range
Min: 6.69  Med: 15.13 Max: 41.19
Current: 6.8
6.69
41.19
P/B 8.54
GSK's P/B is ranked lower than
85% of the 644 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.12 vs. GSK: 8.54 )
Ranked among companies with meaningful P/B only.
GSK' s 10-Year P/B Range
Min: 5.48  Med: 9.11 Max: 19.41
Current: 8.54
5.48
19.41
P/S 2.78
GSK's P/S is ranked higher than
54% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.13 vs. GSK: 2.78 )
Ranked among companies with meaningful P/S only.
GSK' s 10-Year P/S Range
Min: 1.94  Med: 2.90 Max: 4.9
Current: 2.78
1.94
4.9
PFCF 28.53
GSK's PFCF is ranked higher than
65% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.27 vs. GSK: 28.53 )
Ranked among companies with meaningful PFCF only.
GSK' s 10-Year PFCF Range
Min: 8.21  Med: 16.72 Max: 41.33
Current: 28.53
8.21
41.33
POCF 15.96
GSK's POCF is ranked higher than
74% of the 387 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.20 vs. GSK: 15.96 )
Ranked among companies with meaningful POCF only.
GSK' s 10-Year POCF Range
Min: 6.64  Med: 12.61 Max: 20.67
Current: 15.96
6.64
20.67
EV-to-EBIT 6.02
GSK's EV-to-EBIT is ranked higher than
94% of the 488 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.19 vs. GSK: 6.02 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s 10-Year EV-to-EBIT Range
Min: 6.9  Med: 12.00 Max: 240.2
Current: 6.02
6.9
240.2
Shiller P/E 12.49
GSK's Shiller P/E is ranked higher than
89% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.90 vs. GSK: 12.49 )
Ranked among companies with meaningful Shiller P/E only.
GSK' s 10-Year Shiller P/E Range
Min: 10.82  Med: 15.48 Max: 21.15
Current: 12.49
10.82
21.15
Current Ratio 1.31
GSK's Current Ratio is ranked lower than
78% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. GSK: 1.31 )
Ranked among companies with meaningful Current Ratio only.
GSK' s 10-Year Current Ratio Range
Min: 0.97  Med: 1.29 Max: 1.78
Current: 1.31
0.97
1.78
Quick Ratio 0.97
GSK's Quick Ratio is ranked lower than
75% of the 617 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. GSK: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s 10-Year Quick Ratio Range
Min: 0.68  Med: 1.01 Max: 1.42
Current: 0.97
0.68
1.42
Days Inventory 201.52
GSK's Days Inventory is ranked lower than
83% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.66 vs. GSK: 201.52 )
Ranked among companies with meaningful Days Inventory only.
GSK' s 10-Year Days Inventory Range
Min: 151.23  Med: 180.59 Max: 321.53
Current: 201.52
151.23
321.53
Days Sales Outstanding 84.60
GSK's Days Sales Outstanding is ranked lower than
59% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.39 vs. GSK: 84.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s 10-Year Days Sales Outstanding Range
Min: 54.62  Med: 74.32 Max: 112.93
Current: 84.6
54.62
112.93

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 6.03
GSK's Dividend Yield is ranked higher than
96% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. GSK: 6.03 )
Ranked among companies with meaningful Dividend Yield only.
GSK' s 10-Year Dividend Yield Range
Min: 2.72  Med: 4.94 Max: 6.07
Current: 6.03
2.72
6.07
Dividend Payout 0.40
GSK's Dividend Payout is ranked higher than
99% of the 396 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. GSK: 0.40 )
Ranked among companies with meaningful Dividend Payout only.
GSK' s 10-Year Dividend Payout Range
Min: 0.14  Med: 0.69 Max: 6.13
Current: 0.4
0.14
6.13
Dividend growth (3y) 1.90
GSK's Dividend growth (3y) is ranked lower than
64% of the 255 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. GSK: 1.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
GSK' s 10-Year Dividend growth (3y) Range
Min: -12.6  Med: 6.30 Max: 20.8
Current: 1.9
-12.6
20.8
Yield on cost (5-Year) 8.37
GSK's Yield on cost (5-Year) is ranked higher than
96% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. GSK: 8.37 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GSK' s 10-Year Yield on cost (5-Year) Range
Min: 3.76  Med: 6.83 Max: 8.69
Current: 8.37
3.76
8.69
Share Buyback Rate 1.60
GSK's Share Buyback Rate is ranked higher than
94% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. GSK: 1.60 )
Ranked among companies with meaningful Share Buyback Rate only.
GSK' s 10-Year Share Buyback Rate Range
Min: 51.8  Med: 1.20 Max: -20
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.45
GSK's Price/Projected FCF is ranked higher than
76% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. GSK: 1.45 )
Ranked among companies with meaningful Price/Projected FCF only.
GSK' s 10-Year Price/Projected FCF Range
Min: 0.82  Med: 1.53 Max: 7.52
Current: 1.45
0.82
7.52
Price/Median PS Value 0.96
GSK's Price/Median PS Value is ranked higher than
74% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.28 vs. GSK: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
GSK' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.05 Max: 2.59
Current: 0.96
0.69
2.59
Price/Peter Lynch Fair Value 0.86
GSK's Price/Peter Lynch Fair Value is ranked higher than
84% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.79 vs. GSK: 0.86 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GSK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56  Med: 1.36 Max: 3.18
Current: 0.86
0.56
3.18
Earnings Yield (Greenblatt) (%) 16.60
GSK's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. GSK: 16.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GSK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.4  Med: 8.40 Max: 14.5
Current: 16.6
0.4
14.5
Forward Rate of Return (Yacktman) (%) 13.34
GSK's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.18 vs. GSK: 13.34 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GSK' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 4  Med: 13.90 Max: 50.3
Current: 13.34
4
50.3

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 38,338 39,795 41,176
EPS($) 1.10 1.20 1.49
EPS without NRI($) 1.10 1.20 1.49

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GLAXF.USA, GS7.Germany, GSK.Argentina, GSK N.Mexico, GSK.Switzerland, GS7A.Germany,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GSK

Headlines

Articles On GuruFocus.com
ING Aug 27 2015 
ING Aug 27 2015 
ING Aug 27 2015 
ING Aug 27 2015 
Dodge & Cox Acquires Stake in Priceline Aug 21 2015 
AptarGroup: The Leader in Dispensing Innovation Aug 21 2015 
GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma Aug 06 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Tweedy Browne Global Value Adds to Eight Stakes in Portfolio Jul 14 2015 
JW1 Jun 29 2015 

More From Other Websites
Why Growth Is Expected To Take Off At GlaxoSmithKline plc, Barclays PLC, Associated British Foods... Aug 27 2015
GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line... Aug 26 2015
Glaxo in $1 Billion Ofatumumab Deal With Novartis Aug 26 2015
Head To Head: Barclays plc vs GlaxoSmithKline plc Aug 26 2015
Novartis could pay more than $1B for GlaxoSmithKline MS drug Aug 21 2015
Novartis could pay more than $1B for GlaxoSmithKline MS drug Aug 21 2015
Pharmaceutical co. investing $2M in Memphis manufacturing facility previously for sale Aug 21 2015
GSK sells cancer and multiple sclerosis drug to Novartis in $1bn deal Aug 21 2015
GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties Aug 21 2015
Should You Invest In 6%+ Yielders Anglo American plc, HSBC Holdings plc, Ashmore Group plc And... Aug 19 2015
Should You Invest In 6%+ Yielders Anglo American plc, HSBC Holdings plc, Ashmore Group plc And... Aug 19 2015
A GSK layoff helps launch a new RTP drug developer Aug 18 2015
GlaxoSmithKline reopens plant where Legionnaires' found Aug 17 2015
GlaxoSmithKline reopens plant where Legionnaires' found Aug 17 2015
GlaxoSmithKline to reopen plant where Legionnaires' found Aug 14 2015
GlaxoSmithKline to reopen plant where Legionnaires' found Aug 14 2015
Glaxo: Meds from plant with Legionnaires' bacteria are safe Aug 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK